Physician profile
Jacek Grela
NPI 1700850625
$12,232.28
in general payments reported to CMS, 2019-2025
36 companies · $2,148 in 2025
The $2,148 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,198 · 2020: $1,081 · 2021: $1,406 · 2022: $2,069 · 2023: $1,447 · 2024: $1,884 · 2025: $2,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,478.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,739.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,795.04 | 2019-2025 | |
| Lilly USA, LLC | $1,046.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,038.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $882.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $836.94 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $624.99 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $606.75 | 2021-2024 | |
| Amgen INC. | $474.49 | 2019-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $396.92 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $211.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $186.55 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $174.89 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $171.10 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $165.15 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $109.15 | 2019-2020 | |
| Exact Sciences Corporation | $107.50 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $102.04 | 2019-2023 | Verquvo, Steglatro, Lagevrio |
| Astellas Pharma US INC | $69.77 | 2023-2024 | Veozah |
| Corcept Therapeutics | $68.64 | 2025 | Korlym |
| Radius Health, INC. | $54.85 | 2024-2025 | Tymlos |
| Abbott Laboratories | $54.63 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $43.12 | 2022-2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $38.17 | 2024 | Voquezna |
| Viatris Specialty LLC | $29.36 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $26.44 | 2020 | |
| Dexcom, INC. | $23.59 | 2021 | |
| Lundbeck LLC | $22.33 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $21.24 | 2022 | |
| Si-Bone, INC. | $18.40 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.94 | 2024 | Xifaxan |
| Hikma Pharmaceuticals USA | $16.66 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.66 | 2021 | |
| Circassia INC. | $13.77 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacek Grela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.